PreciseDx Collaborates with Baylor Scott & White Health to Validate PreciseBreast™ Assessment for Early-Stage Invasive Breast Cancer Detection

PreciseDx, a leading innovator in oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease analysis, is collaborating with Baylor Scott & White Health in Texas to validate its PreciseBreast™ assessment for early-stage invasive breast cancer.

This first phase will evaluate approximately 300 early-stage invasive breast cancer cases, measuring a concordance comparison between PreciseBreast™ against longitudinal outcomes.

The second phase of the collaboration will analyze and compare the observed event rates of breast cancer recurrence in both low-risk and high-risk recurrence prediction scores against PreciseBreast™. This additional study will further validate the clinical utility of the PreciseBreast™ assessment as a valuable characterization assay for early-stage breast cancer.

Upon successful completion of the 300-patient study, PreciseDx and BS&W will continue to expand the scope to a total of 1,000 patients, providing a more extensive dataset, reinforcing the assessment’s credibility and efficacy.